Myriad Genetics (NASDAQ:MYGN) had its target price raised by Leerink Swann from $33.00 to $35.00 in a research report sent to investors on Wednesday morning. Leerink Swann currently has a market perform rating on the stock. Leerink Swann also issued estimates for Myriad Genetics’ Q3 2018 earnings at $0.27 EPS, Q4 2018 earnings at $0.30 EPS, FY2018 earnings at $1.14 EPS, Q1 2019 earnings at $0.29 EPS, Q2 2019 earnings at $0.29 EPS, Q3 2019 earnings at $0.30 EPS, Q4 2019 earnings at $0.33 EPS and FY2019 earnings at $1.20 EPS.
Other research analysts also recently issued research reports about the stock. ValuEngine upgraded shares of Myriad Genetics from a hold rating to a buy rating in a report on Friday, November 10th. BTIG Research assumed coverage on shares of Myriad Genetics in a report on Friday, January 5th. They set a buy rating and a $41.00 price objective on the stock. Stephens set a $45.00 price objective on shares of Myriad Genetics and gave the stock a buy rating in a report on Wednesday, January 3rd. Barclays boosted their price objective on shares of Myriad Genetics from $30.00 to $35.00 and gave the stock an equal weight rating in a report on Monday, January 22nd. Finally, Zacks Investment Research downgraded shares of Myriad Genetics from a strong-buy rating to a hold rating in a report on Friday, December 15th. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of Hold and an average price target of $31.42.
Myriad Genetics (NASDAQ:MYGN) opened at $32.96 on Wednesday. The company has a market cap of $2,302.26, a price-to-earnings ratio of 28.91, a P/E/G ratio of 2.44 and a beta of 0.32. Myriad Genetics has a twelve month low of $15.71 and a twelve month high of $41.57. The company has a quick ratio of 2.06, a current ratio of 2.05 and a debt-to-equity ratio of 0.05.
In other news, insider Alexander Ford sold 3,031 shares of Myriad Genetics stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $31.64, for a total transaction of $95,900.84. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Richard M. Marsh sold 13,759 shares of Myriad Genetics stock in a transaction dated Friday, January 12th. The shares were sold at an average price of $36.25, for a total transaction of $498,763.75. Following the sale, the vice president now owns 136,385 shares in the company, valued at $4,943,956.25. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 71,064 shares of company stock worth $2,679,097. Insiders own 6.70% of the company’s stock.
Institutional investors have recently modified their holdings of the company. Meeder Asset Management Inc. boosted its position in shares of Myriad Genetics by 1,067.4% during the 3rd quarter. Meeder Asset Management Inc. now owns 3,292 shares of the company’s stock valued at $119,000 after acquiring an additional 3,010 shares in the last quarter. LS Investment Advisors LLC boosted its position in shares of Myriad Genetics by 88.5% during the 4th quarter. LS Investment Advisors LLC now owns 4,791 shares of the company’s stock valued at $165,000 after acquiring an additional 2,250 shares in the last quarter. Commonwealth Equity Services Inc acquired a new stake in shares of Myriad Genetics during the 3rd quarter valued at about $202,000. Teacher Retirement System of Texas acquired a new stake in shares of Myriad Genetics during the 3rd quarter valued at about $204,000. Finally, Shelton Capital Management acquired a new stake in shares of Myriad Genetics during the 3rd quarter valued at about $238,000.
Myriad Genetics Company Profile
Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.